MVAL - ETF AI Analysis

Top Page

VanEck Morningstar Wide Moat Value ETF (MVAL)

Rating:69Neutral

Price Target:―

MVAL, the VanEck Morningstar Wide Moat Value ETF, has a solid overall rating driven mainly by strong, diversified holdings like Merck and Bristol-Myers Squibb, which benefit from robust financial performance, attractive or fair valuations, and promising pipelines or growth portfolios. Additional support comes from quality names such as Danaher and Kenvue, though weaker positions like Boeing and Estée Lauder, which face profitability, leverage, and valuation challenges, hold the fund back somewhat. The main risk factor is exposure to several companies with high debt or overvaluation concerns, which could increase volatility if market conditions worsen.

Positive Factors

Broad Sector Mix in Defensive Areas

The fund spreads its investments across several sectors, with a tilt toward consumer defensive and health care companies that can be more resilient in weaker economies.

Generally Strong Top Holdings

Most of the largest positions, including companies like Constellation Brands, Boeing, and United Parcel, have shown strong year-to-date performance, helping support the ETF’s overall returns.

Positive Recent Performance Trend

The ETF has delivered steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.

Negative Factors

High U.S. Concentration

Almost all of the fund’s assets are invested in U.S. companies, which limits diversification across global markets.

Sector Concentration in a Few Areas

A large share of the portfolio is concentrated in consumer defensive, health care, and industrials, increasing the impact if these sectors face a downturn.

Mixed Performance Among Top Holdings

Some key positions, such as Zimmer Biomet and Campbell Soup, have shown weak year-to-date performance, which can drag on overall returns.

MVAL vs. SPDR S&P 500 ETF (SPY)

AUM5.84M

RegionNorth America

Expense Ratio0.50%

Beta0.72

IssuerVanEck

Inception DateMar 26, 2024

Dividend YieldN/A

Asset ClassEquity

Index TrackedMorningstar US Broad Value Wide Moat Focus Index - Benchmark TR Gross

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume2,089

30 Day Avg. Volume815

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

42.90

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering39

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

MVAL Summary

The VanEck Morningstar Wide Moat Value ETF (MVAL) tracks the Morningstar US Broad Value Wide Moat Focus Index, which focuses on U.S. companies judged to have strong, lasting competitive advantages and to be attractively priced. It holds well-known names like Merck and United Parcel Service (UPS), spread across defensive, health care, industrial, and other sectors. Someone might invest in MVAL to seek long-term growth from high-quality value stocks while staying diversified across many industries. A key risk is that these value stocks can still fall in price and move up and down with the overall stock market.

How much will it cost me?The VanEck Morningstar Wide Moat Value ETF (MVAL) has an expense ratio of 0.49%, which means you’ll pay $4.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed, focusing on selecting companies with strong competitive advantages. Active management typically involves more research and analysis, which can lead to higher costs.

What would affect this ETF?The VanEck Morningstar Wide Moat Value ETF (MVAL) could benefit from long-term growth in sectors like Health Care and Consumer Defensive, which are its largest exposures and tend to perform well during economic uncertainty. However, rising interest rates or economic slowdowns could negatively impact industrial and cyclical sectors, which also make up a significant portion of the ETF's holdings. Regulatory changes or competitive pressures affecting top holdings like Thermo Fisher or Nike may also influence the ETF's performance.

MVAL Top 10 Holdings

MVAL is leaning heavily on steady health care names like Merck and Danaher, which have been quietly rising and helping anchor returns, while consumer staples such as Constellation Brands and Kenvue add a defensive backbone with a bit of upside spark. Industrials are a big swing factor: UPS has been climbing, but Boeing is more of a roller coaster, adding drama as it works through ongoing challenges. On the weaker side, Zimmer Biomet and Campbell Soup are lagging, slightly dragging on an otherwise resilient, U.S-focused, value-tilted portfolio.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
MRK	Merck & Company	5.26%	$308.71K	$301.34B	46.26%	80 Outperform
UPS	United Parcel	5.24%	$307.45K	$101.16B	2.60%	72 Outperform
BMY	Bristol-Myers Squibb	4.89%	$286.97K	$123.70B	12.69%	78 Outperform
STZ	Constellation Brands	4.49%	$263.51K	$25.89B	-8.37%	67 Neutral
BA	Boeing	4.32%	$253.47K	$190.81B	31.74%	54 Neutral
KVUE	Kenvue, Inc.	4.22%	$247.64K	$35.83B	-14.73%	73 Outperform
DHR	Danaher	4.09%	$239.87K	$150.16B	3.04%	75 Outperform
ZBH	Zimmer Biomet Holdings	3.87%	$227.29K	$19.11B	-4.05%	73 Outperform
CPB	Campbell Soup	3.59%	$210.83K	$8.79B	-23.60%	60 Neutral
BF.B	Brown-Forman B	3.26%	$191.20K	$13.92B	-3.85%	74 Outperform

MVAL Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

37.38

Positive

100DMA

35.94

Positive

200DMA

34.17

Positive

Market Momentum

MACD

0.51

Negative

RSI

64.65

Neutral

STOCH

83.70

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MVAL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 38.35, equal to the 50-day MA of 37.38, and equal to the 200-day MA of 34.17, indicating a bullish trend. The MACD of 0.51 indicates Negative momentum. The RSI at 64.65 is Neutral, neither overbought nor oversold. The STOCH value of 83.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MVAL.

MVAL Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
MVAL	―	―	$5.84M	0.50%	―
BAMV	―	―	$98.01M	0.91%	―
TCV	―	―	$92.72M	0.85%	―
GMOV	―	―	$76.83M	0.50%	―
VUSV	―	―	$53.71M	0.30%	―
GVLE	―	―	$42.90M	0.45%	―

Performance Comparison

MVAL

VanEck Morningstar Wide Moat Value ETF

39.16

7.56

23.92%

BAMV

Brookstone Value Stock ETF

―

TCV

Towle Value ETF

―

GMOV

GMO US Value ETF

―

VUSV

Vanguard Wellington U.S. Value Active ETF

―

GVLE

Goldman Sachs Value Opportunities ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents